Obstructive Sleep Apnea Therapeutics Market Size in the 7MM was ~USD 359 Million in 2023, is expected to increase with a significant CAGR of ~ 17% by 2034 | DelveInsight

DelveInsight's "Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the OSA, historical and forecasted epidemiology as well as the OSA market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Obstructive Sleep Apnea Market with DelveInsight's In-Depth Report @ Obstructive Sleep Apnea Market Size [https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Obstructive Sleep Apnea Market Report

* In January 2025:- Eli Lilly and Company- Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.
* In the assessment done by DelveInsight, the estimated Obstructive Sleep Apnea diagnosed prevalent cases in 2023 was highest in the US among the 7MM with 54% cases alone, accounting for nearly 13,763 thousand cases.
* Japan accounted for approximately 20% Obstructive Sleep Apnea diagnosed prevalent cases in the 7MM in the year 2023. It is estimated that these cases will increase with a significant CAGR during the forecast period.
* In the 7MM, in 2023, the analysis reveals the distribution of Obstructive Sleep Apnea Cases by age group where the highest Obstructive Sleep Apnea Prevalence is observed in the 65 years and above age bracket, with ~ 8,870 thousand cases, while the lowest is in the 1924 years group, with ~ 179 thousand cases. This distribution highlights a significant increase in prevalence with age, underscoring the growing impact of OSA in older populations.
* In DelveInsight's Obstructive Sleep Apnea epidemiology model, Obstructive Sleep Apnea is categorized into mild, moderate, and severe types. In 2023, the EU4 and the UK recorded ~2,457 thousand mild; ~1,777 thousand moderate; and ~2,660 thousand severe cases. These figures are projected to rise throughout the forecast period from 2024 to 2034, reflecting an expected increase in Obstructive Sleep Apnea prevalence across all severity levels.
* Among the European countries, France had the highest diagnosed prevalent cases of Dementia with ~ 1,854 thousand cases. Of these cases, males were more affected by OSA, with~1,181 thousand cases, while females had ~673 thousand cases.
* DelveInsight analysis reveals the distribution of Obstructive Sleep Apnea cases in Japan by age group, the highest prevalence is seen in the 65 and above category, with ~1,732 thousand cases, while the lowest is in the 1924 years group, with ~35 thousand cases. This pattern underscores a marked increase in OSA prevalence with advancing age.
* In 2023, the US reported ~4,275 thousand cases of mild Obstructive Sleep Apnea (OSA), ~3,280 thousand moderate cases, and ~6,208 thousand severe cases. These numbers are anticipated to rise steadily from 2024 to 2034, highlighting a trend toward increasing severity in OSA cases.
* The leading Obstructive Sleep Apnea Companies such as Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc, Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc, Apnex Medical Inc , and others
* Promising Obstructive Sleep Apnea Therapies such as SUNOSI (Solriamfetol), AD109 , and others.

Stay ahead in the Obstructive Sleep Apnea Therapeutics Market with DelveInsight's Strategic Report @ Obstructive Sleep Apnea Market Outlook [https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Obstructive Sleep Apnea Epidemiology Segmentation in the 7MM

* Obstructive Sleep Apnea Diagnosed Prevalent Cases
* Obstructive Sleep Apnea Gender-specific Diagnosed Prevalent Cases
* Obstructive Sleep Apnea Age-specific Diagnosed Prevalent Cases
* Obstructive Sleep Apnea Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Obstructive Sleep Apnea epidemiology trends @ Obstructive Sleep Apnea Prevalence [https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Obstructive Sleep Apnea Marketed Drugs

* OZAWADE (Pitolisant): Bioprojet Pharma/Aculys Pharma

OZAWADE is prescribed to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnea (OSA) who do not achieve satisfactory results from primary treatments like CPAP or cannot tolerate such therapies. Discovered by Bioprojet, it received EMA approval in 2021 for obstructive sleep apnea. The FDA approved it in 2019 for narcolepsy-related excessive daytime sleepiness and cataplexy. Pitolisant is a histamine H3 receptor antagonist/inverse agonist, enhances brain arousal and neurotransmitter release.

* SUNOSI (Solriamfetol): Axsome Therapeutics/Jazz Pharmaceuticals/Pharmanovia

SUNOSI, a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI), is used to enhance wakefulness in adults with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

Acquired by Jazz Pharmaceuticals from Aerial Biopharma in 2014, SUNOSI's global rights are held by Jazz, except in 12 Asian markets where SK Biopharmaceuticals retains rights. Administered once daily, SUNOSI's initial dose is 75 mg for narcolepsy and 37.5 mg for OSA, with a maximum of 150 mg. The drug was FDA-approved in March 2019 and received European Commission approval in January 2020 to improve wakefulness in adult patients with EDS associated with narcolepsy or OSA.

Obstructive Sleep Apnea Emerging Drugs

* Tirzepatide: Eli Lilly and Company

Tirzepatide, a once-weekly injectable GIP and GLP-1 receptor agonist, is in Phase III trials for obstructive sleep apnea (OSA). Currently approved for type 2 diabetes, it is also studied for obesity, heart failure with preserved ejection fraction (HFpEF), and nonalcoholic steatohepatitis (NASH). In 2022, it received FDA's Fast Track Designation for weight loss in obesity-related conditions, including OSA.

* Retatrutide: Eli Lilly and Company

In addition to tirzepatide, Eli Lilly is also advancing retatrutide, a triagonist targeting GIP, GLP-1, and glucagon receptors, in Phase III trials for obstructive sleep apnea (OSA). LY3437943 is a biologic agent functioning as a triagonist for the GIP, GLP-1, and glucagon receptors.

* AD109: Apnimed

AD109 is a first-in-class oral medication, administered once daily at bedtime, designed for treating Obstructive Sleep Apnea (OSA) across varying disease severities. This novel combination includes a selective antimuscarinic, aroxybutynin, and a norepinephrine reuptake inhibitor (NRI), atomoxetine. It aims to overcome the limitations of current standard treatments by offering safety, effectiveness, and convenience. Currently, AD109 is undergoing evaluation in two Phase III trials, LunAIRo and SynAIRgy. In May 2022, the FDA designated AD109 for OSA as a Fast Track development program, which makes the program eligible for expedited review by the FDA.

Get In-Depth Knowledge on Obstructive Sleep Apnea Market Trends and Forecasts with DelveInsight @ Obstructive Sleep Apnea Treatment Market [https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Obstructive Sleep Apnea Companies

Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc, Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc, Apnex Medical Inc. and others.

Obstructive Sleep Apnea Treatment Market

The Obstructive Sleep Apnea treatment market landscape includes both pharmacological and non-pharmacological approaches. Non-pharmacological treatments primarily involve positive airway pressure (PAP) therapy, including continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP), which are considered the gold standard. Lifestyle modifications, such as weight loss and positional therapy, also play a crucial role. Pharmacological options include medications like modafinil for excessive daytime sleepiness and newer drugs such as solriamfetol (SUNOSI) for wakefulness. OSA is usually treated by weight management and exercise, CPAP therapy (first line of treatment for OSA), bilevel positive airway pressure (BPAP) machines (if CPAP therapy is not effective), and surgery.

Unlock Strategic Insights with DelveInsight's Comprehensive Obstructive Sleep Apnea Market Report @ Obstructive Sleep Apnea Market Drivers and Barriers [https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Obstructive Sleep Apnea Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Obstructive Sleep Apnea Companies- Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc, Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc, Apnex Medical Inc. and others.
* Obstructive Sleep Apnea Therapies- SUNOSI (Solriamfetol), AD109 , and others.
* Obstructive Sleep Apnea Therapeutic Assessment: Obstructive Sleep Apnea current marketed and Obstructive Sleep Apnea emerging therapies
* Obstructive Sleep Apnea Market Dynamics: Obstructive Sleep Apnea market drivers and Obstructive Sleep Apnea market barriers
* Obstructive Sleep Apnea Unmet Needs, KOL's views, Analyst's views, Obstructive Sleep Apnea Market Access and Reimbursement

Table of Content

1 Key Insights

2 Report Introduction

3 Obstructive Sleep Apnea (OSA) Market Overview at a Glance

4 Epidemiology and Market Methodology of OSA

5 Executive Summary of Obstructive Sleep Apnea

6 Key Events

7 Disease Background and Overview of OSA

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Drugs:

11 Emerging Therapies

12 OSA: Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=obstructive-sleep-apnea-therapeutics-market-size-in-the-7mm-was-usd-359-million-in-2023-is-expected-to-increase-with-a-significant-cagr-of-17-by-2034-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sepsis-market



This release was published on openPR.